+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Therapies - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 915 Pages
  • July 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 834980

Global Cancer Therapies Market to Reach $209.2 Billion by 2026


Cancer is ranked among the leading diseases resulting in mobility and mortality. Cancer treatments or therapies are aimed at eliminating or slowing down growth of cancerous abnormal cells by interfering with specific molecules like DNA or proteins that contribute to growth of cancerous cells. Global market for cancer therapies continues to witness robust growth driven by the increasing prevalence of various types of cancers across the world. Amid the COVID-19 crisis, the global market for Cancer Therapies estimated at US$161.3 Billion in the year 2022, is projected to reach a revised size of US$209.2 Billion by 2026, registering a compounded annual growth rate (CAGR) of 7.1% over the analysis period. The United States represents the largest regional market for Cancer Therapies, accounting for an estimated 38.3% share of the global total. The market is projected to reach US$52.4Billion by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 10.8% over the analysis period.

The development and increased availability of accurate and highly effective treatment options, led by technology advancements and increase investments into R&D indicatives, is expected to fuel growth. The rapid aging population at a higher risk of developing cancer also presents growth opportunities for the market. Standard cancer treatments such as chemotherapy, radiation therapy, surgery, given their relatively higher side effects and disadvantages, are forecast to be elbowed aside by new biotherapy and immunological treatments, which are expected to spruce up growth. New therapies, such as those based on biotechnology, nanotechnology, immunology and stem cell, which kicked off with a smaller base, are expected to witness faster growth chiefly at the expense of conventional therapies. The present cancer therapy pipeline is inundated with novel weapons for targeting cancer, including cancer-killing viruses. However, the significantly higher cost of developing cancer drugs and potential for side effects with various cancer therapies are limiting market growth.
The growing population of cancer patients in the US represents a major growth driving factor. The well-developed healthcare infrastructure facilities in the country and high adoption of technologically advanced treatment methods for cancer are positioning the US as a major player in the cancer therapies market. Asia-Pacific is poised to grow at a high rate due to rising cancer prevalence in the region, increasing awareness about various cancer therapies, and growing collaborations between private and public sectors to offer new cancer therapies in the region. The market for Biotherapies is forecast to emerge as the dominant segment over the analysis period. The segment features several drugs that have attained blockbuster status and sales of these drugs continue to rise with each passing year. Factors such as increasing number of new and overall cancer patients worldwide, as well as the relative higher efficacy and safety profiles of biotherapies are further expected to fuel sales in this segment.

Select Competitors (Total 80 Featured):

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited.

What`s New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to the digital archives
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Cancer Therapies: An Outlook
  • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
  • By Cancer Type
  • USA Leads the Cancer Therapies Market
  • Biotherapies to Drive Growth
  • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
  • Total Number of New Cancer Cases by Type: 2018
  • Total Number of Cancer Deaths by Type: 2018
  • Cancer Incidence by Region: 2018
  • Cancer Mortality by Region: 2018
  • Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
  • Cancer Research Spending Continues to Witness Growth
  • Number of FDA-Approved Cancer Drugs: 2010-2018
  • Select Cancer Drug Approvals in 2019
  • Select Cancer Drug Approvals in 2018
  • Cancer Drug Pipeline to Change the Pharma Landscape
  • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • Cancer Therapies - Global Key Competitors Percentage Market Share in 2022 (E)
  • Select Leading Cancer Drugs Worldwide by Sales: 2018
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
  • AbbVie, Inc. (USA)
  • Amgen, Inc. (USA)
  • Astellas Pharma, Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Select Late Stage Compounds in Bristol-Myers Squibb Company’s Oncology Pipeline (As of 2019)
  • Celgene Corporation (USA)
  • Eli Lilly and Company (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Glaxosmithkline Plc (UK)
  • Johnson & Johnson Services, Inc. (USA)
  • Merck KGaA (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
  • Industry Focuses on New Approaches to Treat Cancer
  • Recent Advancements in Cancer Drug Discovery
  • A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
  • Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
  • New Linker Technology for Enhancing Stability of ADCs
  • Personalized Medicine Gains Importance
  • Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
  • North American Companion Diagnostics Market (2019)
  • European Companion Diagnostics Market by Disease Area (2019)
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
  • Combination Therapy: A Double Whammy Success
  • Patent Expiries of Branded Drugs to Trigger Generic Competition
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
  • Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
  • Development of Novel Drug Candidates and Potential Therapies
  • Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
  • Rise in Patient Assistance Programs (PAPs)
  • Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
  • Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
  • Growth Drivers and Restraints
  • Demographics & Lifestyles Raise the Risk of Cancer
  • Percentage Breakdown of New Cases for All Cancers by Gender (2019)
  • Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
  • Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
  • Unmet Needs Leave Scope for Further Research and Development
  • Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
  • Increasing Investments by National Health Authorities
  • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
  • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
  • Innovations, Improvements, and Approvals Propel Growth
  • Select Cancer Drug Approvals (2018 & 2019)
  • Emerging Challenges in Cancer Drug Development
  • Drug Failures Deter Prospects of New Therapies
  • High Prices of Targeted Therapies Act as a Speed Breaker
  • Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
  • Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
  • Limited Tumor Specificity and Toxicity
  • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  • Reduced Smoking
  • Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
  • Reimbursement Coverage Remains a Major Challenge
  • Increase in Multidrug Resistance
  • Stringent Regulations Delay Market Approval
  • Challenges Encountered in Clinical Trials
  • Overview of Cancer Therapy Segments
  • Immunotherapy: A Promising Segment
  • Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
  • Monoclonal Antibodies for Cancer Treatment
  • Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
  • Vaccines: A Promising Future Area of Cancer Therapeutics
  • Approved Therapeutic Cancer Vaccines Worldwide
  • CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients’ Immune Cells for Cancer Treatment
  • UK Researchers New Approach Holds Potential to Boost Immunotherapies
  • Targeted Therapy: An Overview
  • Types of Targeted Therapy
  • Chemotherapy: An Overview
  • Types of Chemotherapy
  • Risks Associated with Chemotherapy
  • Hormone Therapy
  • Drug Classes in Hormone Therapy
  • CANCER TYPES, APPROVED AND PIPELINE DRUGS
  • Prostate Cancer
  • Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
  • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
  • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
  • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
  • Prostate Cancer Phase IV Completed Clinical Trials with Results
  • Lung Cancer
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Age-Standardized Lung Cancer Rates in Men for Select Countries
  • Age-Standardized Lung Cancer Rates in Women for Select Countries
  • Select FDA-Approved Non-Small Cell Lung Cancer Drugs
  • Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
  • Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
  • Breast Cancer
  • Select FDA Approved Breast Cancer Drugs
  • Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
  • Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
  • Renal Cancer
  • Select FDA-Approved Renal Cell Carcinoma Drugs
  • Cervical Cancer
  • Colorectal Cancer
  • Select FDA-Approved Colorectal Cancer Drugs
  • Skin Cancer
  • Pancreatic Cancer
  • Non-Hodgkin’s Lymphoma
  • Leukemia
  • Standard Approved Mode of Therapy for AML by Age Group
  • Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
  • Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
  • Bladder Cancer
  • Endometrial Cancer
4. GLOBAL MARKET PERSPECTIVEIII. MARKET ANALYSIS
UNITED STATES
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Market Overview
  • Rising Cancer Cases Spur Growth in Cancer Therapies Market
  • Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
  • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
  • Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
  • A Surging US Prostate Cancer Therapeutics Market
  • Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
  • Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
  • CMS Hikes Reimbursement Rate for CAR-T Therapy
  • Market Analytics
CANADA
  • Number of New Cancer Cases in Canada: 2019
JAPAN
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
CHINA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • Cancer Therapies Market: Overview
  • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
  • Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
EUROPE
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
FRANCE
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
GERMANY
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
ITALY
UNITED KINGDOM
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • An Insight into Asia-Pacific Market for Cancer Therapies
  • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
AUSTRALIA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
INDIA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
IV. COMPETITION
  • Total Companies Profiled: 80

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited.